Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: A cross-sectional prospective study

International Journal of Dermatology

Volumn 52, Issue 9, 2013, Pages 1081-1087

  Jacobi, Arnd ^a   Kupke, Carina ^a   Behzad, Melika ^a   Hertl, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; COMORBIDITY; DEPRESSION; DERMATOLOGY LIFE QUALITY INDEX; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NAIL PSORIASIS; PHOTOTHERAPY; PLAQUE TYPE PSORIASIS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RISK ASSESSMENT; SMOKING; SYSTEMIC THERAPY; TOPICAL TREATMENT;

ADULT; AGED; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEPRESSION; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL DISEASES; GERMANY; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 84882686049     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05517.x     Document Type: Article

References (52)

1. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
2. Nast A, Boehncke WH, Mrowietz U, et al. [S3-guidelines for the treatment of psoriasis vulgaris: update 2011]. J Dtsch Dermatol Ges 2011; 9(Suppl. 2): S1-S104.
3. Augustin M, Krüger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
4. Augustin M, Lange S, Wenninger K, et al. Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. Eur J Dermatol 2004; 14: 107-113.
5. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-244.
6. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
7. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17-27.
8. Van Voorhees AS, Fried R. Depression and quality of life in psoriasis. Postgrad Med 2009; 121: 154-161.
9. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
10. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 2000; 70: 567-571.
11. Behnam SM, Behnam SE, Koo JY. Alcohol as a risk factor for plaque-type psoriasis. Cutis 2005; 76: 181-185.
12. Fortes C, Mastroeni S, Leffondré K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005; 141: 1580-1584.
13. Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010; 220: 38-43.
14. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther 2010; 23: 137-143.
15. Boehncke WH, Boehncke S. Managing comorbidities in psoriasis. Actas Dermosifiliogr 2009; 100(Suppl. 2): 22-27.
16. Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med 2009; 122: 1151-1159.
17. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-1251.
18. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-87.
19. Radtke MA, Reich K, Blome C, et al. Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 2009; 219: 54-58.
20. Schöffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007; 5: 209-218.
21. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210: 194-199.
22. Augustin M, Amon U, Braathen L, et al. [Assessment of quality of life in dermatology]. J Dtsch Dermatol Ges 2004; 2: 802-806.
23. Augustin M, Zschocke I, Lange S, et al. [Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis]. Hautarzt 1999; 50: 715-722.
24. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
25. Fredriksson T, Pettersson U. Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. Dermatologica 1979; 158: 60-64.
26. Behnam SM, Behnam SE, Koo JY. Smoking and psoriasis. Skinmed 2005; 4: 174-176.
27. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010; 24: 885-892.
28. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-585.
29. Lavaroni G, Kokelj F, Pauluzzi P, Trevisan G. The nails in psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) 1994; 186: 113.
30. Cantini F, Niccoli L, Nannini C, et al. Psoriatic arthritis: a systematic review. Int J Rheum Dis 2010; 13: 300-317.
31. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 2010; 35: 680-689.
32. Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011; 38: 898-903.
33. Husni ME, Mease PJ. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 2010; 12: 281-287.
34. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011; 131: 1007-1010.
35. Guinot C, Latreille J, Perrussel M, et al. Psoriasis: characterization of six different clinical phenotypes. Exp Dermatol 2009; 18: 712-719.
36. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ 2010; 340: b5666.
37. Boehncke WH, Gladman DD, Chandran V. Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. J Rheumatol 2011; 38: 567-571.
38. Gisondi P, Del Giglio M, Cozzi A, Girolomoni G. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther 2010; 23: 155-159.
39. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009; 218: 110-113.
40. Gisondi P, Dalle Vedove C, Girolomoni G. Patients with psoriasis have a higher prevalence of parental cardiovascular disease. Dermatology 2011; 222: 330-335.
41. Karadag AS, Yavuz B, Ertugrul DT, et al. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasisInt J Dermatol 2010; 49: 642-646.
42. Gelfand JM, Abuabara K. Diet and weight loss as a treatment for psoriasis. Arch Dermatol 2010; 146: 544-546.
43. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-1006.
44. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 771-776.
45. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol 2011; 147: 1031-1039.
46. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585-589.
47. Cohen SS, Weinstein MD, Herndier BG, et al. No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris, or pemphigus foliaceus. J Invest Dermatol 1998; 111: 781-783.
48. Dreiher J, Weitzman D, Davidovici B, et al. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008; 88: 561-565.
49. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-836.
50. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15.
51. Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008; 216: 133-136.
52. Jacobi A, Mahler V, Schuler G, Hertl M. Treatment of inflammatory dermatoses by tumour necrosis factor antagonists. J Eur Acad Dermatol Venereol 2006; 20: 1171-1187.